novonesis

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.

Per November 21, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,464,124 shares, corresponding to 5.01% (previously 4.94%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments is 5.15% (previously 5.08%).

November 25, 2024

Company announcement No. 48

Contact information

Tobias Bjorklund +45 3077 8682 tobb@novonesis.com

Anders Enevoldsen +45 5350 1453 adev@novonesis.com

Katrine Spedtsberg Poulsen kats@novonesis.com

About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

CVR number: 10 00 71 27 - LEI: 529900T6WNZXD2R3JW38

Novozymes A/S, part of Novonesis Group Krogshoejvej 36 2880 Bagsvaerd Denmark